Abstract:Introduction and aim Knowledge about multisystem inflammatory syndrome in children (MIS-C) is still evolving, and evidence-based standardized diagnostic and management protocols are lacking. An analysis of the published evidence can help fill this gap. The aim is to evaluate the clinical and diagnostic features, management strategies, and outcomes of MIS-C and evaluate the variances between high-income countries and lower-middle-income countries (LMIC). Methods Case series, cohorts, case-control, and cross-sectional studies that included the clinical presentation, diagnostic features, management, and outcomes of MIS-C patients with a sample size of ten or more patients were included. PubMed, Cumulative Index of Nursing and Allied Health Literature (CINAHL), Cochrane Library, and LitCovid were searched from December 2019 to March 2023. Forest plots were created for each variable using R. Mean and prevalence ratios were pooled using random effects model. A mixed generalized linear model was employed to account for the heterogeneity and publication bias was assessed via Egger test and Doi plots. The primary outcome was pooled mean and prevalence of MIS-C patient profile variables. Subgroup analysis was conducted based on the income class of the country. Results A total of 120 studies were included. Fever (99%; 95% CI, 99.6–100%), gastrointestinal symptoms (76.7%; 95% CI, 73.1–79.9%), and dermatological symptoms (63.3%; 95% CI, 58.7–67.7%) were frequently observed along with raised inflammatory, coagulation and cardiac markers. Intravenous immunoglobulins (87.5%; 95% CI, 82.9–91%) and steroids (74.7%; 95% CI, 68.7–79.9%) were the mainstays of management. Pediatric intensive care unit (PICU) admission (53.1%; 95% CI, 47.3–58.9%) was likely, but the overall mortality rate was low (3.9%; 95% CI, 2.7–5.6%). Patients in LMIC were younger and more likely to present with respiratory symptoms and develop coronary findings on echocardiogram, IVIG was less frequently used, with a longer hospital and PICU stay, and a higher mortality rate (10%). Conclusion The wide gap in mortality rates between HIC and LMIC shown by our meta-analysis highlights the importance of focusing studies and policies on identifying and addressing this disparity. References 1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. Accessed May 19, 2023. https://covid19.who.int/ 2. Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19. Pediatr Infect Dis J. 2020;39(5):355–368. doi: https://doi.org/10.1097/INF.0000000000002660

Therapeutic Plasma Exchange for a Critically Ill Late Preterm Infant with Multisystem Inflammatory Syndrome of Children: A Case Report and Review of the Literature

Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes

A Case of Severe Multisystem Inflammatory Syndrome in Children (MIS-C) Treated with Multiple Biologics

Efficacy of CytoSorb in a Pediatric Case of Severe Multisystem Infammatory Syndrome (MIS-C): A Clinical Case Report

Treatment of multisystem inflammatory syndrome in children

Therapeutic Plasma Exchange in Pediatric Intensive Care Unit: A Single-center Experience

Extracorporeal Membrane Oxygenation for COVID-19-Associated Multisystem Inflammatory Syndrome in a 5-year-old

Evaluation of the results of the patients who underwent plasmapheresis in the pediatric intensive care unit

A Misdiagnosis of MIS-C: Acute Pneumococcal Meningitis Due to Serotype 19F in A Child with Acute SARS-CoV-2 Infection with a Severe Disease Course

Therapeutic Plasma Exchange in Pediatric Patients: Results from a Single Center

Multisystem inflammatory syndrome in children: A single-center experience

Multisystem inflammatory syndrome in children with COVID-19 in a multitransfused patient

Case report: Thrombotic microangiopathy in pediatric multisystem inflammatory syndrome associated with COVID-19: a case series

Multisystem inflammatory syndrome in children (MIS-C): A nationwide collaborative study in the Greek population

New insight into the intravenous immunoglobulin treatment in Multisystem Inflammatory Syndrome in children and adults

Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management

Clinical presentation, diagnosis and management of multisystem inflammatory syndrome in children (MIS-C): a systematic review

Remestemcel-L Therapy for COVID-19–Associated Multisystem Inflammatory Syndrome in Children

Multisystem Inflammatory Syndrome of Children: Subphenotypes, Risk Factors, Biomarkers, Cytokine Profiles, and Viral Sequencing

All hands on deck: A multidisciplinary approach to SARS-CoV-2-associated MIS-C

Clinical presentation, diagnosis, management and outcomes of multisystem inflammatory syndrome in children (MIS-C)- a systematic review and meta-analysis